Published in J Clin Oncol on March 01, 2000
Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma. Cancer (2009) 3.52
Locoregional therapies for hepatocellular carcinoma: a critical review from the surgeon's perspective. Ann Surg (2002) 2.42
Percutaneous local ablative therapy for hepatocellular carcinoma: a review and look into the future. Ann Surg (2003) 2.21
The prognostic significance of clinical and pathological features in hepatocellular carcinoma. World J Gastroenterol (2002) 2.03
A randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma. Ann Surg (2007) 1.63
Long-term follow-up outcome of patients undergoing radiofrequency ablation for unresectable hepatocellular carcinoma. World J Surg (2005) 1.62
Difference in tumor invasiveness in cirrhotic patients with hepatocellular carcinoma fulfilling the Milan criteria treated by resection and transplantation: impact on long-term survival. Ann Surg (2007) 1.38
Prediction of recurrence and prognosis in patients with hepatocellular carcinoma after resection by use of CLIP score. World J Gastroenterol (2002) 1.19
The influence of hepatitis B DNA level and antiviral therapy on recurrence after initial curative treatment in patients with hepatocellular carcinoma. J Gastroenterol (2009) 1.13
A phase II and pharmacokinetic study of SB-715992, in patients with metastatic hepatocellular carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG IND.168). Invest New Drugs (2008) 1.04
A new staging system for resectable hepatocellular carcinoma: comparison with six existing staging systems in a large Chinese cohort. J Cancer Res Clin Oncol (2010) 1.01
Survival analysis of re-resection versus radiofrequency ablation for intrahepatic recurrence after hepatectomy for hepatocellular carcinoma. World J Surg (2012) 0.93
Enhanced detection of early hepatocellular carcinoma by serum SELDI-TOF proteomic signature combined with alpha-fetoprotein marker. Ann Surg Oncol (2010) 0.92
High-intensity focused ultrasound ablation: an effective bridging therapy for hepatocellular carcinoma patients. World J Gastroenterol (2013) 0.85
A meta-analysis of adjuvant therapy after potentially curative treatment for hepatocellular carcinoma. Can J Gastroenterol (2013) 0.83
The Role of Antiviral Therapy for HBV-Related Hepatocellular Carcinoma. Int J Hepatol (2011) 0.83
Connexin-43 can delay early recurrence and metastasis in patients with hepatitis B-related hepatocellular carcinoma and low serum alpha-fetoprotein after radical hepatectomy. BMC Cancer (2013) 0.82
Factors impacting prognosis prediction in BCLC stage C and Child-Pugh class A hepatocellular carcinoma patients in prospective clinical trials of systemic therapy. Oncologist (2012) 0.82
Risk Factors and Post-Resection Independent Predictive Score for the Recurrence of Hepatitis B-Related Hepatocellular Carcinoma. PLoS One (2016) 0.81
Elevated Preoperative Serum Alanine Aminotransferase/Aspartate Aminotransferase (ALT/AST) Ratio Is Associated with Better Prognosis in Patients Undergoing Curative Treatment for Gastric Adenocarcinoma. Int J Mol Sci (2016) 0.81
Anti-viral therapy to reduce recurrence and improve survival in hepatitis B virus-related hepatocellular carcinoma. World J Gastroenterol (2013) 0.79
Feasibility of laparoscopic re-resection for patients with recurrent hepatocellular carcinoma. World J Surg (2014) 0.79
Influence of Preoperative Serum Aspartate Aminotransferase (AST) Level on the Prognosis of Patients with Non-Small Cell Lung Cancer. Int J Mol Sci (2016) 0.78
RMP predicts survival and adjuvant TACE response in hepatocellular carcinoma. Oncotarget (2015) 0.77
Comparison of Survival Outcomes Between Right Posterior Sectionectomy and Right Hepatectomy for Hepatocellular Carcinoma in Cirrhotic Liver: A Single-Centre Experience. World J Surg (2015) 0.76
[Radiofrequency ablation of hepatocellular carcinoma]. Wien Med Wochenschr (2013) 0.76
Cezanne predicts progression and adjuvant TACE response in hepatocellular carcinoma. Cell Death Dis (2017) 0.75
HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology (2010) 12.32
Sexual transmission and propagation of SIV and HIV in resting and activated CD4+ T cells. Science (1999) 7.66
NURD, a novel complex with both ATP-dependent chromatin-remodeling and histone deacetylase activities. Mol Cell (1998) 7.58
Early treatment of acute biliary pancreatitis by endoscopic papillotomy. N Engl J Med (1993) 5.84
Methylation of histone H4 at arginine 3 facilitating transcriptional activation by nuclear hormone receptor. Science (2001) 5.25
Both corepressor proteins SMRT and N-CoR exist in large protein complexes containing HDAC3. EMBO J (2000) 5.22
Hepatectomy for hepatocellular carcinoma: toward zero hospital deaths. Ann Surg (1999) 4.97
A steroid receptor coactivator, SRA, functions as an RNA and is present in an SRC-1 complex. Cell (1999) 4.65
Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma. Ann Surg (2000) 4.44
Endoscopic biliary drainage for severe acute cholangitis. N Engl J Med (1992) 4.29
Identification and characterization of variable-number tandem repeats in the Yersinia pestis genome. J Clin Microbiol (2001) 4.08
Prospective randomized study of early versus delayed laparoscopic cholecystectomy for acute cholecystitis. Ann Surg (1998) 3.43
Improving survival results after resection of hepatocellular carcinoma: a prospective study of 377 patients over 10 years. Ann Surg (2001) 3.25
Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma. Cancer (2000) 3.23
A prospective study on fish bone ingestion. Experience of 358 patients. Ann Surg (1990) 3.19
Intrahepatic recurrence after curative resection of hepatocellular carcinoma: long-term results of treatment and prognostic factors. Ann Surg (1999) 3.05
Hepatic resection for hepatocellular carcinoma. An audit of 343 patients. Ann Surg (1995) 3.04
Francisella tularensis strain typing using multiple-locus, variable-number tandem repeat analysis. J Clin Microbiol (2001) 2.99
Anterior approach for difficult major right hepatectomy. World J Surg (1996) 2.94
A broad-spectrum human lung fibroblast-derived mitogen is a variant of hepatocyte growth factor. Proc Natl Acad Sci U S A (1991) 2.93
Prospective evaluation of Pringle maneuver in hepatectomy for liver tumors by a randomized study. Ann Surg (1997) 2.83
Lipopolysaccharide induction of the tumor necrosis factor-alpha promoter in human monocytic cells. Regulation by Egr-1, c-Jun, and NF-kappaB transcription factors. J Biol Chem (1997) 2.73
Genetic locus in mice that blocks development of atherosclerosis despite extreme hyperlipidemia. Circ Res (2001) 2.55
Compliance with postoperative instructions: a telephone survey of 750 day surgery patients. Anaesthesia (2001) 2.53
Mismatch repair co-opted by hypermutation. Science (1998) 2.49
Hepatocellular carcinoma in the elderly: results of surgical and nonsurgical management. Am J Gastroenterol (1999) 2.47
Adult-to-adult living donor liver transplantation using extended right lobe grafts. Ann Surg (1997) 2.44
Hospital mortality of major hepatectomy for hepatocellular carcinoma associated with cirrhosis. Arch Surg (1995) 2.37
alpha-synuclein promotes mitochondrial deficit and oxidative stress. Am J Pathol (2000) 2.36
Preoperative endoscopic drainage for malignant obstructive jaundice. Br J Surg (1994) 2.22
A human T lymphocyte differentiation marker defined by monoclonal antibodies that block E-rosette formation. J Immunol (1981) 2.20
HDAC3: taking the SMRT-N-CoRrect road to repression. Oncogene (2007) 2.19
Effects of the intermittent Pringle manoeuvre on hepatic gene expression and ultrastructure in a randomized clinical study. Br J Surg (2003) 2.19
beta-Catenin mutation and overexpression in hepatocellular carcinoma: clinicopathologic and prognostic significance. Cancer (2001) 2.17
Clinical implications of circulating angiogenic factors in cancer patients. J Clin Oncol (2001) 2.15
Antiretroviral resistance during successful therapy of HIV type 1 infection. Proc Natl Acad Sci U S A (2000) 2.13
Factors predictive of 5-year survival after transarterial chemoembolization for inoperable hepatocellular carcinoma. Br J Surg (2003) 2.10
Preoperative chemotherapy versus surgical therapy alone for squamous cell carcinoma of the esophagus: a prospective randomized trial. J Thorac Cardiovasc Surg (1997) 2.09
Antiviral therapy improves post-hepatectomy survival in patients with hepatitis B virus-related hepatocellular carcinoma: a prospective-retrospective study. Aliment Pharmacol Ther (2014) 2.06
Familial colorectal cancer risk by subsite of primary cancer: a population-based study in Utah. Aliment Pharmacol Ther (2015) 2.03
Distribution and molecular analysis of Lyme disease spirochetes, Borrelia burgdorferi, isolated from ticks throughout California. J Clin Microbiol (1993) 2.03
The clinical significance of routine histopathologic study of the resected appendix and safety of appendiceal inversion. Surg Gynecol Obstet (1986) 2.02
Significance of resection margin in hepatectomy for hepatocellular carcinoma: A critical reappraisal. Ann Surg (2000) 2.01
Cilia with defective radial spokes: a cause of human respiratory disease. N Engl J Med (1979) 2.01
A prospective study of operative risk factors in perforated duodenal ulcers. Ann Surg (1982) 2.00
Two cases of acrometastasis to the hands and review of the literature. Curr Oncol (2008) 2.00
The Shatin community mental health survey in Hong Kong. II. Major findings. Arch Gen Psychiatry (1993) 1.99
Pancreatic solid-cystic-papillary tumor: clinicopathologic features in eight patients from Hong Kong and review of the literature. World J Surg (1999) 1.98
Hepatectomy with an ultrasonic dissector for hepatocellular carcinoma. Br J Surg (1996) 1.97
Analysis of reduced death and complication rates after esophageal resection. Ann Surg (2001) 1.96
Adaptive radiation therapy. Phys Med Biol (1997) 1.94
Management of spontaneous rupture of hepatocellular carcinoma: single-center experience. J Clin Oncol (2001) 1.93